Viral clearance occurs very early during the natural resolution of hepatitis C virus infection in persons with haemophilia

Haemophilia

Volumn 10, Issue 1, 2004, Pages 75-80

  Eyster, M Elaine ^a,c   Sanders, J ^a   Goedert, J J ^b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Haemophilia; Hepatitis C; Spontaneous hepatitis C virus RNA clearance

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9 CONCENTRATE; HEPATITIS C ANTIBODY; VIRUS RNA;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMORBIDITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DNA DETERMINATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HEMOPHILIA; HEPATITIS C; HUMAN; IMMUNOASSAY; IMMUNOBLOTTING; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; VIREMIA; VIRUS LOAD;

EID: 1042292586     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1351-8216.2003.00836.x     Document Type: Article

References (23)

1. Alter HJ, Conry-Cantelena C, Melpolder J et al. Hepatitis C in asymptomatic blood donors. Hepatology 1997; 26: 29S-33S.
2. Alter MJ, Margolis HS, Krawczynski K et al. The natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992; 327: 1899-905.
3. Kenny-Walsh, E. For the Irish Hepatology Research Group. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med 1999; 340: 1228-33.
4. Wiese M, Berr F, Lafrenz M, Porst H, Olsen V. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-year multicenter study. Hepatology 2000; 32: 91-96.
5. Vogt M, Lay T, Frosner G et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 1999; 341: 866-70.
6. Rodger AJ, Roberts S, Lanigan A, Bowden S, Brown T, Crofts N. Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971 to 1975. Hepatology 2000; 32: 582-7.
7. Thomas DL, Astemborski J, Rai RM et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000; 284: 450-6.
8. Seeff LB, Hollinger FB, Alter HJ et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis:.a national heart, lung, and Blood Institute Collaborative Study. Hepatology 2001; 33: 455-63.
9. Huang S-J, Lee S-D, Chan C-Y, Lu R-H, Lo K-J. A randomized controlled trial of recombinant interferon α-2b in the treatment of Chinese patients with acute post-transfusion hepatitis C. J Hepatol 1994; 21: 831-6.
10. Giuberti T, Marin MG, Ferrari C et al. Hepatitis C virus following clinical resolution of acute hepatitis C. J Hepatol 1994; 20: 666-71.
11. Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 1999; 29: 908-14.
12. Larghi A, Zuin M, Crosignani A et al. Outcome of an outbreak of acute hepatitis C among healthy volunteers participating in pharmacokinetics studies. Hepatology 2002; 36: 993-1000.
13. Gerlach TJ, Zachoval R, Gruener N et al. Acute hepatitis C: natural course and response to antiviral treatment. Hepatology 2001; 34: 341A.
14. Hofer H, Watkins-Riedel T, Janata O et al. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology 2003; 37: 60-4.
15. Fletcher ML, Trowell JM, Craske J, Pavier K, Rizza CR. Non-A non-B hepatitis after transfusion of factor VIII in infrequently treated patients. Br Med J (Clin Res Ed) 1983; 287:1754-7.
16. Kernoff PBA, Lee CA, Karayannis P, Thomas HC. High risk of non-A, non-B hepatitis after a first exposure to volunteer or commercial clotting factor concentrates: effects of prophylactic immune serum globulin. Br J Haematol 1985; 60: 469-79.
17. Watson HG, Ludlam CA, Rbus S, Zheng LQ, Peutherer JF, Simmonds P. Use of several second generation serological assays to determine the true prevalence of hepatitis C infection in haemophiliacs treated with non-virus inactivated VIII and IX concentrates. Br J Haematol 1992; 80: 514-8.
18. Messick K, Sanders JC, Goedert JJ, Eyster ME. Hepatits C viral clearance and antibody reactivity patterns in persons with haemophilia and other congenital bleeding disorders. Haemophilia 2001; 7: 568-74.
19. Mehta SH, Cox A, Hoover DR. Protection against persistence of hepatitis C. Lancet 2002; 359: 1478-83.
20. Lau JYN, Davis GL, Kniffen J et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993; 341: 1501-4.
21. Barrett S, Kieran N, Ryan E, O'Keane JC, Crowe J. Intrahepatic hepatitis C viral RNA status of serum polymerase chain reaction-negative individuals with histological changes on liver biopsy. Hepatology 2001; 33: 1496-502.
22. McHutchison JG, Poynard T, Esteban-Mur R et al. Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin. Hepatology 2002; 35: 688-93.
23. Marcellin P, Boyer N, Gervais A et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997; 127: 875-81.